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Abraham A. Kroon, MD; Wim N.J.C. van Asten, PhD; and Anton F.H. Stalenhoef, MD
mmmm DO
Background: Apheresis of low-density lipoprotein (LDL) 
is an effective lipid-lowering treatment in hypercholester­
olemic patients who have coronary artery disease and are 
refractory to drugs. More aggressive lipid-lowering ther­
apy may further slow the progression of atherosclerosis.
Objective: To compare the effect of LDL apheresis and 
simvastatin therapy with the effect of simvastatin therapy 
alone on the progression of peripheral vascular disease.
Conclusions: Aggressive lipid lowering with simvastatin 
and LDL apheresis decreased the intima-media thickness 
of the carotid artery and prevented an increase in the 
number of hemodynamically significant stenoses in the 
lower limbs. Therapy with simvastatin alone did not pre­
vent progression of carotid or aortotibial vascular disease.
Ann Intern Med. 1996:125:945-954.
Design: Open, randomized, single-center study.
Setting: University hospital.
Patients: 42 men with primary hypercholesterolemia (to­
tal cholesterol level > 8.0 mmol/L) and extensive coronary 
atherosclerosis.
Intervention: Biweekly apheresis of LDL plus simvasta-
tin, 40 mg/d (n = 21), or simvastatin, 40 mg/d (n = 21), for 
2 years.
Measurements: Lipid and lipoprotein levels, changes in 
hemodynamically significant stenoses in the aortotibial 
tract (measured by ankle:arm systolic blood pressure ratio 
combined with Doppler spectrum analysis of the femoral 
artery), and changes in the mean intima-media thickness 
of three carotid artery segments.
Results: Mean baseline LDL cholesterol levels decreased 
from 7.8 to 3.0 mmol/L in the apheresis and simvastatin 
group and from 7.9 to 4.1 mmol/L in the simvastatin-only 
group; mean lipoprotein(a) levels decreased from 57.0 to
44.5 mg/dL (change, -“ 19%) in the former group and in­
creased from 38.4 to 44.5 mg/dL (change, 15%) in the 
latter group. In the apheresis group, the number of pa 
tients with hemodynamically significant stenoses in the 
aortotibial tract decreased from 9 to 7; in the simvastatin- 
only group, the number increased from 6 to 13 (P = 0.002). 
Mean intima-media thickness decreased by a mean ± SD 
of 0.05 ± 0.34 mm in the apheresis group and increased by 
0.06 ± 0.38 mm in the simvastatin-only group (P < 0.001). 
According to multiple regression analysis, changes in apo- 
lipoprotein B, total cholesterol, and lipoprotein(a) levels 
accounted for changes in the aortotibial tract (R2 = 0,36); 
changes in lipoprotein(a) and apolipoprotein A1 levels 
accounted for changes in the intima-media thickness of
the carotid artery (R2 0.49).
From University Hospital Nijmegen, Nijmegen, the Netherlands. 
For current author addresses, see end of text.
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ntil recently, intensive lipid lowering using 
3-hydroxy-3~methylglutaryl coenzyme A
CoA) reductase inhibitors has been the most effec­
tive way to slow or stop the progression of coronary
atherosclerosis and reduce
events in men
of
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coronary artery disease. Our objective was to deter- 5.0 mmol/L; and 4) extensive coronary atheroscle-
mine whether the very aggressive lowering of LDL rosis, as shown by visual assessment of the baseline 
cholesterol levels with LDL apheresis plus simvasta- coronary angiogram. Patients were excluded if they
tin, a potent HMG-CoA reductase inhibitor (23), had had a coronary event in the 3 months before
has a better antiatherosclerotic effect than does the study enrollment; had impaired hepatic or
lowering of lipid levels to more conventional levels renal function, hypertension, diabetes mellitus, severe
using simvastatin alone. The results of the primary obesity, hyperhomocysteinemia, homozygous famil-
outcome— changes in coronary arteiy disease as as- ial hypercholesterolemia, and any secondary hyper-
sessed by quantitative analysis of results of sequen- lipidemia; or if they smoked more than 10 cigarettes
tial coronary angiography and exercise tolerance per day.
tests were recently described elsewhere (22). Patients were recruited from the outpatient clin
Ultrasonographic techniques are important surro- ics of the cardiology and internal medicine depart-
gate variables for clinical end points in quantitative ments of the University Hospital of Nijmegen. Pa-
measurements of atherosclerotic manifestations (24). tients who were eligible at the end of a 2-month
The ankle:arm systolic blood pressure ratio at rest run-in period were randomly assigned to receive
and during hyperemia is a reproducible way to de- either biweekly apheresis of LDL plus simvastatin
termine the presence of arterial insufficiency in the (40 mg/d) or simvastatin (40 mg/d) alone. Random-
lower limbs (25). To differentiate between hemody- ization was stratified for the serum total cholesterol
namically significant stenoses located in the aorto- and lipoprotein(a) levels, age, and the presence or
iliac or the femorotibial tract, measurement of this absence of previous coronary artery bypass graft
pressure ratio should be combined with measure­
ment of blood flow velocities in the common fem-
surgery
Apheresis of LDL was done using an automated
oral artery by using Doppler spectrum analyses (26, system that contained two small dextran sulfate cel- 
27). High-resolution B-mode ultrasonography of the lulose columns (MA-01 unit, Liposorber, Kanegafu- 
carotid arteiy is also an effective and accurate way chi Chemical Industry Co., Osaka, Japan); these
to assess atherosclerotic changes of the arterial wall columns selectively absorb lipoproteins that contain
(28, 29). This technique has been applied in several apolipoprotein B and thereby reduce the level of
studies, and the intima-media thickness of the ca- very-low-density lipoprotein (VLDL), LDL, and li- 
rotid artery has been shown to reflect generalized poprotein(a). A volume of 5000 mL was treated per
atherosclerosis, which is indicated by the association session, and the process took to hours. Patients
of the intima-media thickness with coronary athero 
sclerosis and lower-extremity atherosclerosis (30-34).
To evaluate the effect of lipid lowering on pro 
gression of peripheral vascular disease in hypercho
in the simvastatin-only group visited the outpatient
clinics each month Patients in both treatment
groups also received a resin at the highest tolerable
dose serum cholesterol levels exceeded 8 . 0
lesterolemic patients with severe coronary artery mmol/L for 2 consecutive months; we considered it 
disease, we sequentially assessed hemodynamically inappropriate to continue single-drug treatment when 
significant stenoses in the lower extremities and the cholesterol levels were this high. At each visit, a
intima-media thickness of the carotid arteiy We brief physical examination was done and patients
present the results of this assessment and relate were given additional dietary instructions. Adher-
them to changes in lipid and lipoprotein levels. enee to drug therapy was established by counting 
pills.
Methods
Patients and Treatment
Biochemical Variables
In the apheresis group, lipid and 
were measured biweekly 
ately after each apheresis m
immedi-
t.
The design of LAARS has been described else- tin-only group, these levels were measured monthly.
where (35). Briefly, eligibility criteria included
male sex; age between 30 and 67 years; the
Apolipoprotein Al, apolipoprotein lipopro-
tein(a) levels were measured bimonthly in both
following lipid levels, measured in persons receiving groups. Serum total cholesterol and fasting triglyc- 
a standard lipid-lowering diet (American Heart As- eride levels were determined by using enzymatic
sociation step I) but no other lipid-lowering treat- assays (cholesterol: cholesterol oxidase-phenol ami-
ment: a) two successively measured serum total cho- nophenazone peroxidase [CHOD-PAP], Boehringer 
lesterol levels with an average exceeding 8.0 mmol/L Mannheim, Mannheim, Germany; triglycerides: Sera-
or an LDL cholesterol level greater than 5.8 PAK, Miles 3 High-density lipoprotein (HDL)
mmol/L and b) two successively measured fasting cholesterol levels were measured by using the poly
serum triglyceride levels with an average less ethylene glycol 6000 precipitation method (36). Lev-
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els of LDL cholesterol were calculated by subtract- sure in the dorsalis pedis or posterior tibial
ing HDL cholesterol and VLDL cholesterol from artery were used. Hemodynamically significant vas-
total cholesterol. Samples of apolipoprotein A1
apolipoprotein and lipoprotein(a) levels were
cular disease was defined as an at-rest ankle:arm
blood pressure ratio less than 0.90 or a
stored at -8 0  °C; levels were measured at the end decrease of the pressure ratio during reactive hy- 
of the study. Apolipoprotein A1 and apolipoprotein peremia of 0.20 or greater.
levels were quantified in serum by immuno- For evaluation of the results, patients were cate-
nephelometry (37), and lipoprotein(a) levels were gorized according to changes in stenosis. Patients 
measured by using a specific radioimmunoassay with at least one new hemodynamically significant
[apolipoprotein(a) radioimmunoassay 100, Phar- lesion in the aortoiliac or femorotibial tract of ei-
macia Diagnostics AB, Uppsala, Sweden]. ther side were considered to have worsened. Pa-
Lipoprotein levels are increased after completion tients in whom the number of lesions decreased and
of LDL apheresis used to selectively remove li- stable patients who no difference in the
poproteins contain apolipoprotein B. This in- number or location of *
crease can be explained by first-order kinetics (38). stenoses were considered to have
Therefore, time-averaged concentrations (CA V or patient needed angioplasty or vascular
a
for
interval mean levels of total cholesterol, LDL cho- progressive claudication, he was considered to have
lesterol, apolipoprotein B, and lipoprotein(a) were worsened, regardless of the outcome of the test.
calculated applying a formula derived from the
area under the rebound curve:
MAX0.73 (C
treatment and
M IN), where
AVO MIN
MAX is the level before
MIN is the level immediately after
Measurements of the Intima-Media Thickness of 
the Carotid Artery
High resolution B-mode ultrasonography of the
apheresis (22). We used only pretreatment levels of carotid arteiy was also done once a year. Ultra­
serum triglycerides and HDL cholesterol because sonography could not be done at baseline in the
triglycerides reach pretreatment levels within to first patients that were enrolled because the method
days after apheresis and HDL cholesterol is not was not available at the start of the study. We could
influenced by LDL apheresis.
done
Measurement of the Ankle:Arm Systolic Blood 
Pressure Ratio and Doppler Spectrum Analyses
Measuring blood flow velocities in the common from a fixed latero-lateral angle by using a duplex 
femoral artery by using Doppler spectrum analysis apparatus (ACUSON 128XP, Cardia-Acuson B.V.,
therefore evaluate three sequential measurements 
(including the baseline measurement) in 11 patients 
in both groups and two measurements in the re­
maining patients. Longitudinal scans were
has proven to be an accurate, noninvasive easily Mountain View, California) equipped with
performed screening test for assessing functionally L7384 linear array/5.0-MHz Doppler transducer; an
and hemodynamically significant stenoses in the aor- atomical landmarks were the com
totibial tract (26, 27). Staff at the vascular labora- mon carotid artery and the flow in
tory who were blinded to treatment assignment
measured blood flow velocity at baseline, at year ?
arotid artery. Great care was taken to 
double-line pattern from the near and far walls. The
and at 2 years. In a single session, blood flow ve- intima-media thickness was defined
locities in common femoral artery and ankle:
the
in millimeters between the lumen-intima and a H P 1 W
arm systolic blood pressure ratios in both limbs adventitia interfaces. Although the md far wall
were recorded at rest and during reactive hyper 
emia. Analyses done during reactive
thigh cuff compression have been shown 
to enhance the sensitivity for detecting abnormali­
ties of the aortoiliac tract (39). Doppler signals were
are not identical anatomical
can
study
wall
%/ * *. I c of
% *
> I *
in an
varu
com-
obtained from the common femoral artery by using measurement. If a plaque was located in the section
an 8-MHz bidirectional continuous-wave Doppler 
apparatus (Angiodine 2, D.M.S., Montpellier, France), 
with the probe placed just below the inguinal
sured,
tima
the intima-media
plaque was
thickness value.
should
in
> i \  «
in
ment. Maximum-frequency waveforms were calcu- images of the arterial 
lated from the spectra. As has been described else- time on a videotape. Follow-up scans
ultrasonographic 
stored in real-
5>
where (39, 40), several variables that describe the 
shape of the waveforms were used. The same Dopp-
probe was used to determine the ankle:arm 
tolic blood pressure ratio; for this measurement, the 
systolic radial artery pressure and the highest pres-
were by the
the the study, 
off-line at
who
intima
blinded to treatment
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signment. The intima-media complex of the common 
carotid artery (the segment 10 mm proximal to the
dilatation), bifurcation (the segment between
Results
Baseline Characteristics
the fiow divider and the dilatation), and the internai 
carotid artery (the segment 10 mm distal to the flow
Twenty men were enrolled in each group
the baseline characteristics of groups are
divider) was measured by using a semi-automated shown in Table 1. Sixteen patients in each group 
contour detection program. For each patient, we were heterozygous for familial hypercholesterolemia 
obtained a mean intima-media thickness from 12 (76% of the study sample). Risk factors for athero-
combined arterial sections sides ? walls, and sclerosis were equally distributed. All patients had
segments) as a measure of wall thickness. To esti- severe angiographically shown coronary atheroscle- 
mate the intraobserver variability, we invited 10 ran- rosis. Stenosis of 50% or greater was considered 
domly selected patients to have repeated assessment significant; according to this criterion, 17 of 21 men
of intima-media thickness 7 days after the initial in the apheresis group and 19 of 21 men in the
assessment. The coefficient of variation, computed simvastatin-only group had three-vessel coronary ar­
as the proportion of the SD of the overall mean, tery disease. The other patients had two-vessel dis-
was 11.5% (intraobserver error, 0.10 mm). ease. Four men in apheresis group and eight
Statistical Analysis
men in the simvastatin-only group had a history of 
stroke or intermittent claudication. Baseline choles­
terol levels were high, and most patients had ele-
Analyses were done using the Student /-test and vated levels of lipoproteins that contained apoli-
multivariate analysis of variance for normally dis- poprotein B according to inclusion criteria (Table
tributed data and the Mann-Whitney U test for 2). Lipoprotein(a) levels showed a skewed distribu-
differences in the means of data that were not nor- tion: Median baseline levels were 28.8 mg/dL in the
mally distributed. Differences in proportions were apheresis group and 19.8 mg/dL in the simvastatin-
analyzed using the Yates corrected chi-square test only group. The treatment groups were well bal-
and analyses for trends in proportions were done anced, and no significant differences were seen be-
Mantel-Haenszel chi-square tween the groups in baseline characteristics or lipidusing the extended
test. We did stepwise least-squares multivariate re- and lipoprotein levels.
gression analysis using a maximal P value in the 
test of 0.05 before a variable could be added and a Clinical Events and Patient Evaluation
minimal tolerance (collinearity) of 0.01. Analyses 
were based on the randomly assigned treatment
group (intention to treat). A two-sided P value of 
less than 0.05 was considered significant. Results are 
expressed as the mean ± SD, and differences be­
tween within-group changes are shown with 95% 
CIs. We used SPSS software (SPSS Inc., Chicago,
Illinois) for all analyses.
Two patients, one in each group, had progressive
intermittent claudication. The patient from the
apheresis group had to have angioplasty of the 
common iliac artery 5 months after the study began. 
The same patient had coronary artery bypass graft
surgery for unstable angina at 9 months; after this 
procedure, the patient received simvastatin only.
s patient in the simvastatin-only group who had 
progressive claudication had abdominal aortic
surgery after 12 months of treatment.
Table 1. Baseline Characteristics*
Characteristic Apheresis and Simvastatin-
Simvastatin Only
Group Group
(n = 21) (n =•■ 21)
->v. n-pV'p >>' .r.i,,j v>'.v.v..p.(i, fi\p-.i n> ! - t ;  pjip i.'i ■' rsi,jvm"'i-'**u."“ , p , » i . ' ¿ i * . . . P S ' S , , , t ; --------17 - •■«■-i - T- ■ ---- -
Age, y 50.2 ± 9.6
>■>*■»< rii rr>ft.ryi-,n "an'* < », 1 m',<— »^»«1iytm
53.9 ± 8.7
Body weight, kg 81.5 ± 9.7 80.8 ± 8.6
Body mass index, kg/m2 26.6 ± 2.0 26.2 ± 2.0
Systolic blood pressure, mm Hg 129.3 ± 17.3 126.3 ±18.1
Diastolic blood pressure, mm Hg 78.2 ± 8.9 76.5 ± 9.0
Current smokers, n (%) 3(14.3) 4(19.0)
Myocardial infarction, n (%) 16(76.2) 18(85.7)
Coronary artery bypass graft surgery, n (%) 10(47.6) 10(47.6)
Percutaneous transluminal coronary
angioplasty, n (%) 2 (9.5) 5 (23.8)
Hypertension, n (%) 2 (9.5) 5 (23.8)
Stroke, n (%) 1 (4.8) 3 (14.3)
Claudication, n (%) 3(14.3) 5 (23.8)
One patient in the apheresis group 
follow-up because he died immediately
j -  j i , .
c coro­
nary 
months
done
study
unstable angina within 
. Thus,
20 patients in the apheresis group and 21 
the simvastatin-only group could be
Lipid and Lipoprotein Profiles
Three patients in the apheresis group and 4 in
the simvastatin-only group received additional resin
treatment, 8 to 24 g of cholestyramine per day.
Apheresis of LDL reduced mean total cholesterol 
levels by 62%, reduced mean LDL cholesterol 
by 78%, reduced mean lipoprotein(a) levels by 71%,
■ vi i f ■\ m jrt ' SD or number (percentage) of patients. Baseline characteristics
did riot differ significantly between groups.
and reduced mean apolipoprotein B levels by 
Levels of HDL cholesterol were not affected by this
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Table 2. Changes in Lipid and Lipoprotein Levels*
Variable Apheresis and Simvastatin Group Simvastatin-Only Group Difference between P Value for
(n = 21) (n == 21) Within-Group Changes Difference
b  r .  -M  .  —  -■ » ! ■ !  I I M 1  —  . . .  M » .  ■ — ■ ■ ■ ■ — .  » . . .  . f c » . .  . .  -  . . . »  .  -  — -  .......... (95% Cl) between. . . i  ( « u n i i  '  i m a  * 1  i  ■ J I M  *  f i i p w i
Baseline Value Percentage Change Baseline Value
l U ' V r W  p ^ .1  . . .  1  | n . .  1  \ .  o *  I  *  *  M k i f i  . M l *  M l '  . 4 * 1  1 4 J  •  '  1 ► " 1  1 1 ,1 1
Percentage Change Treatment
Groupst
Total cholesterol, mmol/L 9.72 ± 1.84 — 52.9% ±  5.6% 9.85 ± 2.17 -39.5%  ± 7.7% —13.4 (—17.9 to —8.9) <0.001
Triglycerides, mmol/L 2.32 ± 1.03 — 17.4% ± 24.4% 2.64 1.33 -26.5%  ± 20.3% 9.1 (-4 .9  to 23.1) >0.2
Low-density lipoprotein
cholesterol, mmol/L 7.78 ± 1.86 -62.9%  ±  8.3% 7.85 ± 2.34 -47.4%  ± 8.1% — 15.5 (—20.6 to ~~10.4) <0.001
High-density lipoprotein
cholesterol, mmol/L 0.93 ±0.18 17.7% ± 13.6% 0.92 H h 0.19 13.7% ± 10.9% 4.0 (-3 .7  to 11.7) >0.2
Lipoprotein(a), mg/dL 57.0 ± 63.9 -18.6%  ±  18.0% 38.4 Ì 39.7 14.9% ± 16.3% -33.5  (~~44.2 to —23.8) <0.001
Apolipoprotein B, g/L 2.59 ± 0.47 -49.0%  ±  7.6% 2.60 ± 0,61 -31.0%  ± 17.0% ■“ 18.0 (—26.2 to —9.8) <0.001
Apolipoprotein A1, g/L 1.43 ± 0.29 -5.3%  ± 13.0% 1.46 ± 0.38 — 5.4% ± 16.8% 0.1 (—9.3 to 9.5) >0.2.
* Values are the mean ± SD. To convert total cholesterol values to mg/dL, multiply by 38.67; to convert triglyceride values to mg/dL, multiply by 88.57. 
t Mann-Whitney U test or r-test.
procedure. Differences in treatment effects were attributable to an increase in the number of ferno
totablished by comparing interval mean levels in the rotibial lesions (from 
apheresis group with mean levels in the simvastatin- tients with abnormalities of the 
only group. During the study, levels of lipoprotein creased from
The number of
tract in
to the group the
containing apolipoprotein B were significantly lower total number of patients with hemodynamically sig
in the apheresis group than in the simvastatin-only nificant lesions decreased from to this statisti
group (Table 2). In both groups, the increase in cally insignificant change caused significant differ- 
HDL cholesterol levels and the decrease in serum ences in trends between both groups at the end of
triglyceride levels were similar during simvastatin the study 0.002; Figure I). The number of
treatment (Table 2). The LDL:HDL cholesterol ra- patients who had abnormalities of the aortoiliac
tio was reduced from 8.4 to 2.7 change of tract decreased from to
67%
0.003), and the
7%) in the apheresis group and from 8.5 number of patients with femorotibial stenoses de-
to 3.9 (a change of 53% 7%) in the simvasta- creased from to (P <  0.001). Eighteen of 20
tin-only group (difference between groups, 14.5% patients in the apheresis group and of 21
[95% Cl, 9.9% to 19.1%]). The interval mean lipo- patients in the simvastatin-only group showed a re 
protein(a) level was reduced by 19% to 44.5 ±54.3 duction or no change in the number of hemodynam- 
mg/dL in the apheresis group; this reduction was ically significant stenoses in the whole aortotibial 
statistically significantly different from the 15% in­
crease (to 44.5 ± 45.7 mg/dL) seen in the simva- 
statin-only group (Table 2).
i
Hemodynamically Significant Lesions in the 
Aortoiliac and Femorotibial Tract
At baseline, the number of patients with stenoses 
in the whole aortotibial tract did not significantly
between the groups: The ankle:arm systolic 
blood pressure ratio was abnormally low in nine
= 0.002) (relative 
When we categorized 
showed an increase 
change or a reduction in 
namically significant stenoses, the 
of total cholesterol, LDL cholesterol,
2.4 [Cl, 1.3 to 4.2]).
who 
number of
who
no
in levels
in apheresis group and six m
(Aa
o 16
in
the simvastatin-only group. In four patients, 
Doppler spectrum of the femoral artery was abnor-
; five patients had a decreased ankle:arm systolic 
blood pressure ratio that represented hemodynami­
cally significant lesions of the aortoiliac tract. Fem­
orotibial lesions, as shown by a normal Doppler 
spectrum and a decreased ankleiarm systolic blood 
pressure ratio, were found in eight patients in the 
apheresis group and four patients in the simvasta- 
tin-only group. At the end of the study, the number 
of patients in the simvastatin-only group who had 
hemodynamically significant stenoses had increased
•5 12
• t-M
or,o
<
-C
8
0J»J
to
4
a
2 Years
to
rT
s* >*•
ƒ
,.fr
i ,
LDL Apheresis plus 
Simvastatin
Simvastatin Only
Figure 1. The number of patients with hemodynamically signifi­
cant stenoses in the aortotibial tract at baseline and at 2 years of 
treatment with low-density lipoprotein (LDL) apheresis plus simva-
from to 13 (Figure 1). This change was primarily statistically significant (P 0.002),
simvastatin alone. The change in trend between both is
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Table 3. Change in Lipid and Lipoprotein Levels in Patients Showing an Increase in the Number of Hemodynamically
Significant Stenoses in the Aortoiliac and Femorotibial Tract Compared with Patients Showing No Change o 
Reduction in the Number of Stenoses*
Variable
u i iw p «)Uiyt
Total cholesterol, mmol/L 
Triglycerides, mmol/L 
Low-density lipoprotein 
cholesterol, mmol/L 
High-density lipoprotein 
cholesterol, mmol/L 
Lipoprotein(a), mg/dL 
Apolipoprotein B, g/L 
Apolipoprotein A 1 ,  g/L
Patients with Worsened Patients with No Change or
Stenosis (n 15) Improvement in Stenosis (n 26)
*jp ..................... i
Baseline Value Percentage Change Baseline Value Percentage Change
H9H ihl' » li .......... i ■ 11 i n i» *  »'»Hi i t n m m w i 11 ■ iw  in  itf » «TWKWim npi'M tm iiiiin im i pm m m .....nifm iri
9.75 2 .19
2.75 ±  1,24
37 .8 %  ±  7 .7%  
2 5 .7 %  ±  14.4%
9.89 ±  1.92
2.49 1.27
49 .2 %  ±  7 .8%  
25 .3%  ±  16.1%
3 4 4 6 .6 %  ±  7 .2% 7.91 ±  2 .07 58.3%  ±  9 .3%
0.93 ±  0 .19  
4 4 .0  ±  40 .9  
2.65  ±  0 .58  
1.50 ±  0 .38
11.0%  ±  9 .2%
1 2 . 0 %
3 2 .9 %
16.2%
14.8%
0.95 ±  0 .19  
47.3 ±  60.5  
2.56 ±  0 .54
1.43 0.31
15.9%  ±  12 .6%  
12.8%  ±  16 .3%
44 .7%  ±  12.1%  
- 1 .0 %  ±  14.7%
Difference between 
Within-Group Changes
(95%  Cl)
■UimKfi h i n  Ï I i xi» n i i 'i
11.4 (6.4 to 16.4) 
0.4 ( - 1 0 . 6  to 9.8)
11.7(6.1  to 17.3)
-4 .9  (~  12.4 to 2.6) 
24 .8 (14 .1  to 35.5) 
11.8 (3.2 to 20.4)
1.8 ( - 1 1 .2  to 7.6)
P Value for 
Difference
between Groupst
■VMn ..... ...................................................................... ---------------------1 .  , , L .  | ) | W f r -
<0.001
> 0 . 2
<0.001
> 0 . 2
0.002
0.007
> 0 . 2
* No differences in baseline levels were seen between groups. Values are the mean t  SD. To convert total cholesterol values to mg/dL, multiply by 38.67; to convert triglyceride values 
to mg/dL, multiply by 88.57. 
t  Mann-Whitney U test or f-test,
and apolipoprotein B were significantly greater in baseline, did not differ from those in the entire study 
the group that had no change or a reduction (Table group (data not shown). At baseline, the intima- 
3). Indeed, significant correlations were found be- media thicknesses of the bifurcation and the inter­
tween the worsening or improvement of lesions in nal carotid artery were significantly different be- 
the aortotibial tract and absolute changes from tween groups (Table 4). During the study, however,
baseline in levels of total cholesterol 0.46),
LDL cholesterol
0.30), and lipoprotein(a)
the mean intima-media thickness of all carotid seg­
ments gradually and significantly decreased in the 
0.44). This correlation apheresis group; in contrast, the thickness in the
0.38), apolipoprotein
indicates that more aggressive lipid lowering was simvastatin-only group increased. Categorization of 
associated with a reduction in the number of hemo- patients into those who had reduction or no change
dynamically significant stenoses. Multiple regression in mean intima-media thickness 11) and those
analyses showed that the following variables ac who had increased thickening 11) again
counted for changes in the aortotibial tract: mean showed that reductions in levels of total cholesterol,
apolipoprotein B level during the study 0.19
[Cl, 0.10 to 0.22]; P =  0.005), absolute change from 
baseline in total cholesterol levels (b = 0.20 [Cl, (data similar to 
0.12 to 0.28]; P  =  0.005), and absolute change from changes in
LDL cholesterol, lipoprotein(a), and apolipoprotein 
were significantly greater in the former group
shown in Table <md that
baseline in lipoprotein(a) levels 0.16 [Cl, 0.07 Al
serum triglyceride, and
(data notnot
to 0.24]; 0.01). Stepwise addition of other vari- shown). According to
ables did not further significantly improve the vari- change in mean intima
aní
ance (total 2 0.36; 0.001).
Intima-Media Thickness of the Carotid Artery
Baseline concentrations of lipids and lipoproteins 
of the group of 22 men in whom intima 
thickness was measured three times, including at
plained 
levels
absolute changes in
0.07 to
was ex-
A 1
lipoprotein(a) m tm m.TOWteQojtr
0.004). No other £
improved total
md
0.43 [Cl, 0.23 to 0.63];
further
0.49: 0.002).
Table 4„ Change in Mean Intima-Media Thickness in Carotid Artery Segments
Location Apheresis and Simvastatin Group Simvastatin-Only Group
(n 1 1 ) (n 1 1 )......................... . . ................ . ' » XI *” « ' / i i w  ¡ J i m Wt ,  «1 r fM u  * -h<*. • ‘-■yftòti.'JtUx \ ;.V ' "  V 1' -  *>*'
Baseline In tim a-  
Media Thickness
Change Baseline Intim a- 
Media Thickness
Change
mm % mm %
..........................................................i ...................................................................... . u r i ' i i  .............................................................................  . . ......................................................................... ..» .n  w
Bifurcation
Common carotid artery 
Internal carotid artery 
All carotid artery segments
1.11 ±  0 .5 4  
0.81 ±  0 .1 8  
0.83  ±  0 .2 7  
0.91 ±  0 .3 8
0.13 ±  0.47  
0.05 ±  0.12  
0 .04  ±  0,30  
0.05  ±  0 .34
0.92 ±  0 .29  
0.80 ±  0.22
0.91 •Ma 0.37
0.88 ±  0 .30
0,16 ±  0.46  
0.03 ± 0.27  
0.03 ±  0.39  
0.06 ±  0.38
>n
Within-Group Changes
(95%  Cl)
f Lrh'^ nrf-¡TA-TV-,/r-UA*í^ h<J»1 lAU.fÿ* JIV^  |^ t 1— ^  W t...... ■ ; I • '•J'».¿JV\.,J' ■ -t* ■ * i-»<v•
0.29 ( - 0 . 4 4  to 0.14)
,i t*». fj.
•i
0.02
0.07 u-*.;'.
0 .08  to 0.04) 
0 .20  to 0.06)
0.11 ( 0 .1 8  to 0,04)
* Values are the mean ± SD and were obtained in a subgroup of 22 patients, 
t  Multivariate analysis of variance.
P Value for
tween
' ¡•f/j 1^1 > " , /|wfV l**S f  > ■ 1‘.‘ 1 ' «“i I. ‘ • I < , ,'1 •• 1 _fr, ; , I............................. , _ l .  . V .  . I
....V . . / ' 'I ......... .I . . . . .  k. .... . J I. LOI ... .1 . • i,'I I I ,.ll I . {.l»u.....Si . «.I • 1. _(•«•• •. I
0,001
0 . 2
0 , 2
0,001
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reduction in mean intima-media thickness the
carotid artery and the reduction of hemodynami­
cally significant stenoses in the aortotibial tract, ex­
pressed as categorical changes (worsened, stable, or
improved) 0.13 [Cl, 0.07 to 0.311; 0.048)
or as a change in a score that describes the shape of
the Doppler spectrum waveforms 0.21 [Cl,
0.15 to 0.281; 0.009) (Figure (39).
Discussion
Change in Doppler Spectrum Analysis Score
Figure 2. Correlation between the change in mean intima-media 
thickness of the carotid artery and the change in the score of the 
Doppler spectrum analysis (negative values indicate worsening).
LDL-Apheresis Atherosclerosis Regression 
Study (22) evaluated whether veiy aggressive 
lowering in men with extensive coronary artery 
ease more effectively slows the progression of ath­
erosclerosis; changes in the extent of coronary ar­
tery disease were primary outcome measures. Our remarkable; these patients do not seem to have 
study focused on secondary outcome measures. We benefited from cholesterol-lowering drug therapy, 
showed that LDL apheresis plus simvastatin treat- However, the placebo groups in CLAS, MARS, and
ment prevented an increased prevalence of hemo- the Pravastatin to Limit Atherosclerosis in Cor
dynamically significant stenosis in the aortotibial onary arteries (PLAC-II) study (14)—all of which
tract and reduced the mean intima-media thickness enrolled persons with coronary artery disease and
of the carotid artery. Two years of very aggressive had a mean in-trial LDL cholesterol level similar to
lipid-lowering treatment (apheresis plus simvastatin) that in our simvastatin-only group—showed progres-
reduced the size of early peripheral atherosclerotic sion of carotid intima-media thickness. Moreover,
lesions and arrested progression of advanced le- patients in KAPS (10) who received pravastatin
sions; conventional treatment did not prevent pro- (LDL cholesterol level, 3.5 mmol/L) still showed
gression of early or advanced peripheral lesions. progression of carotid intima-media thickness in
Several studies (6-10) have shown the effect of the Asymptomatic Carotid Artery Progression Study
lipid lowering on femoral atherosclerosis. Only one (ACAPS) (13), intima-media thickness decreased in 
uncontrolled study (9) showed the beneficial effect patients to whom lovastatin was given to decrease
Thus al-of LDL apheresis in patients with arteriosclerotic LDL cholesterol levels to 2.9 mmol/L
obliterance. Both the Program on the Surgical Con- though there are important differences
trol of Hyperlipidemias (POSCH) (7) and the Cho- studies and although we analyzed only
lesterol Lowering Atherosclerosis Study (CLAS) (8) group of patients, our data seem to highlight the
showed that long-term lipid-lowering therapy re- fact that very aggressive therapy to decrease LDL
duced the extent of angiographically determined cholesterol levels is necessary to reduce the progres-
femoral atherosclerosis in patients with established sion of atherosclerosis in both
coronary heart disease. These findings agreed with 
ours. However, in the population-based Kuopio 
Atherosclerosis Prevention Study (KAPS) (10),
reduce the annual rate of progression of the intima 
media thickness of the femoral arteries. Some stud-
beds.
Our results confirm the
real
of extracorpo-
LDL
pravastatin treatment decreased LDL cholesterol cholesterol 
levels from 4.9 mmol/L to 3.5 mmol/L but did not first study of apheresis
LDL levels by
to the  ^ d.:\Ik] at
ies (10-14) have also shown a decrease in or re- used lipid-lowering drugs plus
duced progression of the carotid arteiy intima 
media thickness during lipid-lowering therapy. After 
years of treatment, the CLAS investigators
On the other hand, the 47% in LDL
cholesterol seen in our simvastatin-only
may be considered 
showed that the mean intima-media thickness of (23). This reduction
good
the of
the
0.05
common carotid artery was reduced by
0.06 mm; the Monitored Atherosclerosis Re-
quent monitoring of 
The effect of
gression Study (MARS) (12) showed a decrease of atherosclerosis 
0.06
similar to the decrease seen in our apheresis group. shown to be more
0.11 mm at 2 years. These decreases are
The findings in our simvastatin-only group are enee peripheral
on of
arterial segments.
, and c
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and lipoproteins (44, 45). In LAARS, only the ef- The safety and efficacy of LDL apheresis in
fects of changes in lipid and lipoprotein levels could LAARS have been reported elsewhere (22). In gen- 
be analyzed. The observed correlations with total eral, adverse events are infrequent and similar to
those seen with any extracorporeal treatment. Thelevels of cholesterol, apolipoprotein B, apolipopro
tein A l, and lipoprotein(a) agree with data from most frequently reported adverse effects are hypo- 
population-based and intervention studies (46-48). tension and chills; frequencies of these conditions 
The influence of lipoprotein(a) as a risk factor range from o.2% to 1.1% and 0.3% to 6.0%, re­
spectively (17, 22, 51). The efficacy of the treatment 
depends on the lipid levels before and after treat­
ment and on the return of lipids to plasma after 
treatment (38, 54). The combination of LDL apheresis 
and simvastatin therapy can be expected to reduce
rate of the rebound in serum cholesterol after
should be discussed in more detail because LDL 
cholesterol apheresis is one of the few treatments 
that can reduce the concentration of this substance 
(49). The reduction of lipoprotein(a) levels in our 
apheresis group may be somewhat limited: The in­
crease in lipoprotein(a) levels related to simvastatin 
treatment was also seen in the simvastatin-only 
group. This result has also been seen in other re­
ports (22, 50). Still, significantly different trends in 
lipoprotein(a) levels were seen in both groups, and 
multiple regression analysis indicated an important 
relation with change in lipoprotein(a) levels. How- 
ever, decreasing LDL levels may be as important 
for the outcome because mean lipoprotein(a) levels 
during the study were the same in both treatment 
groups. The Familial Hypereholesterolaemia Re- 
gression Study (20) recently showed that further 
reduction of lipoprotein(a) levels by LDL choles-
apheresis;
less, LDL
effect permits prolongation of
sis sessions (54).
?done a
major commitment for the 
high cost of this treatment, 
nity. Therefore, LDL should
and, given the
commu-
reserved
for the few patients who meet the criteria for the
lesterolemia, coronary artery disease, and resistance
to drug treatment
In conclusion, our results confirm that hypercho-
terol apheresis did not further slow the progression lesterolemic patients with established coronary ar-
of coronary artery disease compared with drug tery disease or peripheral vascular disease should be
treatment, which decreased LDL cholesterol levels treated with a combination of lipid-lowering therapy
to the same extent. This finding indicates that the until LDL cholesterol levels are decreased to less
lipoprotein(a) level is less important when com- than 3.0 mmol/L. The combination of LDL aphere-
bined with low LDL cholesterol levels. However, the sis and cholesterol-lowering drugs in patients with a
Familial Hypereholesterolaemia Regression Study did high risk for cardiovascular events is feasible and
not include patients with elevated lipoprotein(a) has been shown to extent of
levels. Thus, in our patients, who had elevated LDL 
cholesterol levels, decreases in lipoprotein(a) 
may account for part of the effect on peripheral 
vascular disease.
is plausible to criticize the results from Dopp- 
spectrum analyses and ankle:arm systolic blood
vascular disease. However, 
considered only in 
terolemia ; 
treatment.
are to combined drug
pressure ratio measurements if one presumes that 
rheologic changes induced by LDL apheresis influ­
enced the results. Indeed, early improvements in the
authors
apheresis unit, the staff of the
for assistance and 
the analysis of the videotapes at the
staff of
Interuni­
symptoms of claudication and
gin a assumed to be induced
blood (9, 51).
an-
correc- Grun t
4 # « a n t from Dutch
tion of rheologic properties 
ductions by dextran-sulfate 
factor VIII, and other coagulation factors have been
tion and by Merck, Sharp, & Dohme, Haarlem, the I I*
» Dohme also
isis unit were
reported to last no longer than 
Still, viscosity of whole blood
to days (52) 
has
den, Germany
fi ) r t h e
shown to be reduced for as long as 1 week (53). 
Thus, we cannot exclude the possibility that im­
proved rheology influenced the measurements of
if, MD,
of Medicine, 541 AI G
8, PC) Box
hemodynamic stenosis after year of treatment
(while apheresis was still being done). At study end,
however, the assessments were done to weeks
after the last treatment; rheologic changes had dis­
appeared by that time.
Dr.
Dr. Kroon:
;h 1, PO
of Internal
x 5800,
*
« , 810
Box 9101, 6500
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Dr. Stalenhoef: Department of Internal Medicine, 541 AIG, Uni­
versity Hospital Nijmegen, Geert Grooteplein 8, PO Box 9101, 
6500 HB Nijmegen, the Netherlands.
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LIBITUM
Medical Marriage
Since she had always dreamt
of making love on a beach
and he was dreaming of furrowed fields
they figured it was time
And as soon as the youngest fell off 
to his nest below their bed 
and the events of the day had 
drifted to the corners of the room 
they took the deeply planted 
signs to be what they meant to be 
and embraced
Later, after two more phone calls
they marvelled at their jerry-built lives
at the Rubegoldbergian blueprint
they swore once again to revise
and sang the praises of soundly sleeping children
answering machines and other small gifts
only God could have devised
Martin Kohn, PhD 
Rootstown, OH 44272
